GB1013192A - Diagnostic reagent composition for use in determining blood coagulation factors - Google Patents

Diagnostic reagent composition for use in determining blood coagulation factors

Info

Publication number
GB1013192A
GB1013192A GB4282162A GB4282162A GB1013192A GB 1013192 A GB1013192 A GB 1013192A GB 4282162 A GB4282162 A GB 4282162A GB 4282162 A GB4282162 A GB 4282162A GB 1013192 A GB1013192 A GB 1013192A
Authority
GB
United Kingdom
Prior art keywords
thromboplastin
composition
blood coagulation
coagulation factors
diagnostic reagent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB4282162A
Inventor
Raphael Cohen
Jane Grant Lenahan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Pharmaceutical Co filed Critical Warner Lambert Pharmaceutical Co
Priority to GB4282162A priority Critical patent/GB1013192A/en
Publication of GB1013192A publication Critical patent/GB1013192A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A lyophilized diagnostic reagent composition for use in determining blood coagulation factors during treatment with anticoagulant agents comprises a tissue thromboplastin composition wherein the thromboplastin comprises from 100-0% of rabbit lung thromboplastin and from 0-100% of rabbit brain thromboplastin, a source of calcium ion and adsorbed bovine plasma and a high concentration of Factor V and fibrinogen, the said composition being buffered to a pH of 7,2-7,6. Specification 917,012 is referred to.ALSO:A lyophilized diagnostic reagent composition for use in determining blood coagulation factors during treatment with anticoagulent agents comprises a tissue thromoplastin composition wherein the thermoplastin comprises from 100 to 0 per cent of rabbit being thromboplastin and from 0 to 100 per cent of rabbit brain thromboplastin, a source of calcium ion and adsorbed bovine plasma and a high concentration of Factor V and fibrinogen, the said composition being buffered to a pH of 7.2 to 7.6. Specification 917,012 is referred to.
GB4282162A 1962-11-13 1962-11-13 Diagnostic reagent composition for use in determining blood coagulation factors Expired GB1013192A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB4282162A GB1013192A (en) 1962-11-13 1962-11-13 Diagnostic reagent composition for use in determining blood coagulation factors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB4282162A GB1013192A (en) 1962-11-13 1962-11-13 Diagnostic reagent composition for use in determining blood coagulation factors

Publications (1)

Publication Number Publication Date
GB1013192A true GB1013192A (en) 1965-12-15

Family

ID=10426124

Family Applications (1)

Application Number Title Priority Date Filing Date
GB4282162A Expired GB1013192A (en) 1962-11-13 1962-11-13 Diagnostic reagent composition for use in determining blood coagulation factors

Country Status (1)

Country Link
GB (1) GB1013192A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0241613A1 (en) * 1986-04-17 1987-10-21 Bio/Data Corporation Improved tableted blood plasma microconcentrated thromboplastin coagulation reagent and method of making same
WO2015040441A1 (en) * 2013-09-19 2015-03-26 Diagon Ltd. Procedure and measuring system for determining blood coagulation characteristics
CN111638374A (en) * 2020-06-08 2020-09-08 深圳市国赛生物技术有限公司 In-vitro diagnostic kit for determining prothrombin time

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0241613A1 (en) * 1986-04-17 1987-10-21 Bio/Data Corporation Improved tableted blood plasma microconcentrated thromboplastin coagulation reagent and method of making same
US4755461A (en) * 1986-04-17 1988-07-05 Bio/Data Corporation Tableted blood plasma microconcentrated thromboplastin coagulation reagent
WO2015040441A1 (en) * 2013-09-19 2015-03-26 Diagon Ltd. Procedure and measuring system for determining blood coagulation characteristics
CN111638374A (en) * 2020-06-08 2020-09-08 深圳市国赛生物技术有限公司 In-vitro diagnostic kit for determining prothrombin time

Similar Documents

Publication Publication Date Title
Ratnoff et al. The activation of Christmas factor (factor IX) by activated plasma thromboplastin antecedent (activated factor XI)
Osterud et al. Factor V activity of platelets: evidence for an activated factor V molecule and for a platelet activator
ATE113213T1 (en) DEVICE FOR PRELIMINARY REPERFUSION TREATMENT OF HEART ATTACK SYMPTOMS.
Kiesselbach et al. Fibrin-stabilizing factor: a thrombin-labile platelet protein
von Kaulla et al. The effect of heparin on components of the human fibrinolytic system
ES2035920T3 (en) AEROLIZATION OF THERAPEUTIC PROTEIN AGENT.
SE8000470L (en) TISSUE BINDING AND PROCEDURE FOR ITS MANUFACTURING AND USING THE BINDING AGENT
ES249137A1 (en) Reagent and method for determining the coagulability of blood
NL190268B (en) METHOD FOR PREPARING A BLOOD CLOTTING PROMOTING PREPARATION BASED ON HUMANE PROTEINS.
ATE66374T1 (en) PREPARATIONS AND METHODS FOR TREATMENT OF BLOOD DISORDERS.
DE59109048D1 (en) Inhibitors for the anticoagulant pretreatment of blood samples
Henderson et al. The thrombotic activity of activation product
Ogston et al. The plasminogen content of thrombi
US4364861A (en) Blood-coagulation-promoting products and methods of preparing them
ES398962A1 (en) Enzyme composition and process for the manufacture thereof
Penick Some factors that influence utilization of antihemophilic activity during clotting.
AU4626389A (en) Use of minoxidil for wound healing
SE7608174L (en) PROCEDURE FOR PREPARING ANTISERUM
ATE2090T1 (en) PROCESS FOR THE MANUFACTURE OF PLASMINOGEN ACTIVATOR, ACTIVATOR SO OBTAINED AND MEDICATION CONTAINING THEM.
GB1013192A (en) Diagnostic reagent composition for use in determining blood coagulation factors
Tager Studies on the nature and the purification of the coagulase-reacting factor and its relation to prothrombin
US2175090A (en) Purification of antibody compositions
ATE2049T1 (en) MEANS OF THERAPY OF IMMUNOCOMPLEX DISEASES.
McClaughry et al. Nature of an accelerator of prothrombin activation arising during storage of purified prothrombin.
Green A simple method for the purification of factor VIII (antihemophilic factor) employing snake venom